<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the plasma chain-breaking <z:chebi fb="11" ids="22586">antioxidants</z:chebi> <z:chebi fb="0" ids="28425">alpha carotene</z:chebi>, <z:chebi fb="9" ids="17579">beta carotene</z:chebi>, <z:chebi fb="0" ids="15948">lycopene</z:chebi>, Vitamin A, <z:chebi fb="122" ids="21241">Vitamin C</z:chebi>, Vitamin E and a measure of total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity, <z:chebi fb="44" ids="53498">TAC</z:chebi>, in 79 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), 37 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), 18 patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> and <z:hpo ids='HP_0000726'>dementia</z:hpo> (PDem), and 58 matching controls, together with 41 patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) and 41 matching controls </plain></SENT>
<SENT sid="1" pm="."><plain>Significant reductions in individual <z:chebi fb="11" ids="22586">antioxidants</z:chebi> were observed in <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0000726'>dementia</z:hpo> groups </plain></SENT>
<SENT sid="2" pm="."><plain>When compared to controls, the following were reduced: Vitamin A in AD (p &lt; 0.01) and VaD (p &lt; 0.001); <z:chebi fb="122" ids="21241">Vitamin C</z:chebi> in AD (p &lt; 0.001), VaD (p &lt; 0.001) and PDem (p &lt; 0.01); Vitamin E in AD (p &lt; 0.01) and VaD (p &lt; 0.001); <z:chebi fb="9" ids="17579">beta carotene</z:chebi> in VaD (p = 0.01); <z:chebi fb="0" ids="15948">lycopene</z:chebi> in PDem (p &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15948">Lycopene</z:chebi> was also reduced in PDem compared to AD (p &lt; 0.001) and VaD (p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="11" ids="22586">Antioxidant</z:chebi> levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> were not depleted </plain></SENT>
<SENT sid="5" pm="."><plain>No significant change in <z:chebi fb="44" ids="53498">TAC</z:chebi> was seen in any group </plain></SENT>
<SENT sid="6" pm="."><plain>The reduction in plasma chain-breaking <z:chebi fb="11" ids="22586">antioxidants</z:chebi> in patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> may reflect an increased <z:chebi fb="19" ids="26519">free-radical</z:chebi> activity, and a common role in <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> in these conditions </plain></SENT>
<SENT sid="7" pm="."><plain>Increased <z:chebi fb="19" ids="26519">free-radical</z:chebi> activity in VaD and PDem could be associated with concomitant AD pathology </plain></SENT>
<SENT sid="8" pm="."><plain>Individual <z:chebi fb="11" ids="22586">antioxidant</z:chebi> changes are not reflected in <z:chebi fb="44" ids="53498">TAC</z:chebi> </plain></SENT>
</text></document>